Back to Newsroom

Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)

Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, today announced the completion of an international, multicenter, non-comparative phase III study with triptorelin embonate (pamoate) 22.5 mg 6-month formulation in 44 patients (39 girls and 5 boys) with central precocious puberty (CPP). The mean age of the patients at the time of diagnosis was 7 years (range 1 to 9 years).

Click here to read more